02529: Understanding the Genetics of Adverse Drug Reactions in Sighthounds: Phase II

Grant Status: Closed

Grant Amount: $229,085
Michael H. Court, BVSc, PhD; Washington State University
June 1, 2018 - September 30, 2023

Sponsor(s): Greyhound Club of America, Irish Wolfhound Club of America, Inc., Orthopedic Foundation for Animals, Saluki Health Research, Inc., Scottish Deerhound Club of America

Breed(s): -All Dogs
Research Program Area: General Canine Health
Donate to Support this Research Program Area

Abstract

Life-threatening unanticipated reactions to drugs with a narrow margin of safety, such as those used for anesthesia and to treat cancer, are a common yet serious concern for dog owners and veterinarians.  Investigators at Washington State University have been conducting research to identify the cause of extremely slow recovery from anesthesia in a high proportion of Greyhounds, as well as in other sighthound breed dogs, including Italian Greyhounds, Scottish Deerhounds, Borzois, Irish Wolfhounds, Salukis, Afghan Hounds, and Whippets (among others). In previous work funded by the AKC Canine Health Foundation (#02242), the investigators discovered several mutations that were shown by cell-based testing to significantly decrease the function of genes responsible for breaking down (metabolizing) commonly used anesthetic drugs, as well as many other drugs used in dogs.  The goal of this next phase of research is to develop a novel drug sensitivity test using saliva, blood or urine samples to identify dogs within a breed (or specific breeds) that metabolize drugs very slowly, thus creating a “personalized” or individual dog approach to drug selection. This test will then be used to confirm that the identified gene mutations are the cause of slow drug metabolism in sighthound dog breeds – as well as identify other breeds and individual dogs that could suffer from similar adverse drug reactions.

Publication(s)

Martinez SE, Pandey AV, Perez Jimenez TE, Zhu Z, Court MH (2024) Pharmacogenomics of poor drug metabolism in greyhounds: Canine P450 oxidoreductase genetic variation, breed heterogeneity, and functional characterization. PLoS ONE 19(2): e0297191. https://doi.org/10.1371/journal.pone.0297191

Mealey, K. L., Martinez, S. E., Villarino, N. F., & Court, M. H. (2019). Personalized medicine: going to the dogs? Human Genetics. https://doi.org/10.1007/s00439-019-02020-w

Martinez, S. E., Shi, J., Zhu, H.-J., Jimenez, T. E. P., Zhu, Z., & Court, M. H. (2019). Absolute quantitation of drug metabolizing cytochrome P450 enzymes and accessory proteins in dog liver microsomes using label-free standard-free analysis reveals inter-breed variability. Drug Metabolism and Disposition, dmd.119.088070. https://doi.org/10.1124/dmd.119.088070

Martinez, S. E., Andresen, M. C., Zhu, Z., Papageorgiou, I., & Court, M. H. (2020). Pharmacogenomics of poor drug metabolism in Greyhounds: Cytochrome P450 (CYP) 2B11 genetic variation, breed distribution, and functional characterization. Scientific Reports, 10(69). doi:10.1038/s41598-019-56660-z

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617
(888)-682-9696

Tax ID# 13-3813813

  

© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.